The proceeds will be use to accelerate the construction of its antibody manufacturing lines.
Antibody discovery CRO Biointron recently announced its completion of a Series B financing round valued at nearly CNY 500 million.
The round was jointly invested by more than 10 venture capitals including Costone Capital (Chinese: 基石资本), Jifeng Ventures (Chinese: 济峰资本), Gaorong Capital (Chinese: 高榕资本), Tianhui Capital (Chinese: 天汇资本) and Haitong Venture Capital (Chinese: 海通创投). The existing investors Furong Investment (Chinese: 复容投资)and CS Capital (Chinese: 承树投资) also participated in this round.
The proceeds will be mainly used to expand its CRO service capacity, The amount of this round of financing will mainly be used for the expansion of CRO service capacity, the construction of intelligent manufacturing R&D service production line, and the continued strengthening of overseas channel construction.
Founded in 2012, Biointron specializes in antibody discovery CRO services. Biointron has R & D and production bases in Zhoupu, Shanghai, Taizhou, Jiangsu, China and business and logistics bases in the United States. It also has established a technology platform covering the whole process of antibody discovery, from target protein development, single B cell antibody screening, to antibody humanization, antibody affinity maturation, nano antibody development, stable cell line development and so on. Up to now, Biointron has provided end-to-end R&D service support for thousands of global pharmaceutical R&D enterprises, in vitro diagnostic reagent enterprises, vaccine enterprises, cell therapy enterprises and other downstream enterprises of life science industry chain.
Companies also provide CRO services include Merry Bio (Chinese: 铭研生物), Neuron Smart (Chinese: 纽伦智能) and Huateng Biomedical (Chinese: 华腾生物).